Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Gemcitabine/Platinum in Advanced Squamous NSCLC
NCT05312840Phase 2Completed
- Sponsor
- Quzhou People's Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, gemcitabine, Cisplatin micelle injection (HA132), carboplatin in squamous cell carcinoma of the lung (SCCL), sponsored by Quzhou People's Hospital. Started Jan 2022; status: completed.
02
Drugs
sintilimabgemcitabineCisplatin micelle injection (HA132)carboplatin
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05312840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05312840.